Bristol-Myers and the activist investors at Starboard have had their say on the pending $74 billion Celgene merger. Some influential voices—namely proxy advisers—have yet to weigh in, though, and their verdicts could sway undecided shareholders ahead of the crucial April
read moreIs the allegation that Novartis made dubious payments to top-ranking Greek officials a political witch hunt or a real case worthy of criminal charges? Preliminary findings from a Novartis internal probe seem to support the former conclusion, as do results
read moreBiogen’s worst fears have come true with the failure of its phase 3 Alzheimer’s prospect aducanumab. And with one of its key blockbusters under threat, it may be “buy or be bought” time for the Big Biotech. More: Where can
read moreIt didn’t always look certain, but on Wednesday, Jazz Pharma’s Sunosi scored an FDA approval to help narcolepsy and sleep apnea patients stay awake. But the new drug can’t roll onto the market until it clears a separate regulatory hurdle
read moreThe European Union has announced it is to give The University of St Andrews 4.37 million Euros for a medical data study. More: EU gives Uni of St Andrews 4.37m Euros for medical data study Source: News
read morePfizer has announced a collaboration with Vivet on the development of a potential breakthrough therapy for Wilson disease. More: Pfizer buys stake in French gene therapy company Vivet Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals